Prospective, Multicenter Surveillance Study of Candida glabrata : Fluconazole and Itraconazole Susceptibility Profiles in Bloodstream, Invasive, and Colonizing Strains and Differences between Isolates from Three Urban Teaching Hospitals in New York City ( Candida Susceptibility Trends Study, 1998 to 1999)
Open Access
- 1 October 2002
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 46 (10) , 3268-3272
- https://doi.org/10.1128/aac.46.10.3268-3272.2002
Abstract
Since the 1990s, the substantial increase in the rate of Candida glabrata infections has become a serious problem. As most C. glabrata infections arise from the host9s endogenous microflora, the present prospective, multicenter analysis included all clinical isolates associated with colonization and with systemic and hematogenous candidiasis. Among 347 C. glabrata isolates, the overall rates of resistance to fluconazole (MIC ≥ 64 μg/ml) and itraconazole (MIC ≥ 1 μg/ml) were 10.7 and 15.2%, respectively, although for half (n = 148) of the itraconazole-susceptible isolates the MICs (0.25 to 0.5 μg/ml) were in the susceptible—dependent upon dose range. Fluconazole resistance was more common among C. glabrata isolates obtained from centers caring for patients with cancer (MICs at which 90% of isolates are inhibited [MIC90s] = 32 μg/ml) or AIDS (MIC90s > 64 μg/ml) than among C. glabrata isolates from a community-based university medical center (MIC90s = 16 μg/ml) (P = 0.001). Thirty-three bloodstream isolates and those obtained from other body sites had similar in vitro susceptibility profiles. The fluconazole MIC90s (≤16 μg/ml) for C. glabrata yeast isolates from the gastrointestinal tract were lower than those (≥64 μg/ml) for C. glabrata isolates from respiratory and urinary tract samples (P = 0.01). A similar discrepancy for itraconazole was not significant (P > 0.5). We did not observe differences in fluconazole or itraconazole susceptibility profiles among C. glabrata isolates associated with either hematogenous dissemination or colonization. The significant discrepancy in antifungal susceptibility among C. glabrata organisms isolated from hospitals in the same geographic region emphasizes the significance of periodic susceptibility surveillance programs for individual institutions, especially those providing care to patients at risk.Keywords
This publication has 36 references indexed in Scilit:
- Prospective evaluation of Candida species colonization in hospitalized cancer patients: impact on short-term survival in recipients of marrow transplantation and patients with hematological malignanciesBone Marrow Transplantation, 2002
- Candida glabrata and Candida krusei fungemia after high-risk allogeneic marrow transplantation: no adverse effect of low-dose fluconazole prophylaxis on incidence and outcomeBone Marrow Transplantation, 2001
- Evolution of Antifungal Susceptibility amongCandidaSpecies Isolates Recovered from Human Immunodeficiency Virus–Infected Women Receiving Fluconazole ProphylaxisClinical Infectious Diseases, 2001
- International Surveillance of Bloodstream Infections Due to Candida Species: Frequency of Occurrence and In Vitro Susceptibilities to Fluconazole, Ravuconazole, and Voriconazole of Isolates Collected from 1997 through 1999 in the SENTRY Antimicrobial Surveillance ProgramJournal of Clinical Microbiology, 2001
- Fungemia in HIV-Infected Patients: A 12-Year Study in a Tertiary Care HospitalAIDS Patient Care and STDs, 2001
- Prospective Study of Candida Species in Patients at a Comprehensive Cancer CenterAntimicrobial Agents and Chemotherapy, 2001
- Risk Factors and Predictors of Outcome in Patients with Cancer and Breakthrough CandidemiaClinical Infectious Diseases, 2001
- Cross-Resistance of Clinical Isolates ofCandida albicansandCandida glabratato Over-the-Counter Azoles Used in the Treatment of VaginitisMicrobial Drug Resistance, 2000
- Prospective Multicenter Surveillance Study of Funguria in Hospitalized PatientsClinical Infectious Diseases, 2000
- Development of Interpretive Breakpoints for Antifungal Susceptibility Testing: Conceptual Framework and Analysis of In Vitro-In Vivo Correlation Data for Fluconazole, Itraconazole, and Candida InfectionsClinical Infectious Diseases, 1997